Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

gene editing

Gene therapy leaders aim to help more Baby KJs with novel regulatory models

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” session focused on the need to expedite more bespoke gene editing treatments like the one that saved young KJ Muldoon.

April 27, 2026

5 min read

Heather McKenzie

Psychedelics

FDA awards priority vouchers to 3 undisclosed companies for investigational psychedelics

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s descriptions of the awarded products match those in development at Compass Pathways, Transcend Therapeutics and Usona Institute.

April 24, 2026

3 min read

Heather McKenzie

Journalism. Camera and photos. Mass media, television, interview, breaking news, press conference concept. Flat vector

Editorial

BioSpace elevates journalism as biopharma evolves in the Trump era

Neal and Azbee awards have validated our approach to reporting on the industry at a time of unprecedented shifts at the FDA and other federal agencies.

April 24, 2026

4 min read

Jef Akst

Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.

Earnings

Daiichi Sankyo shares slip after delaying annual earnings report

Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. That same day, the pharma expects to release its five-year business plan.

April 24, 2026

2 min read

Tristan Manalac

Dashed line from pills isolated on white

Pipeline

Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.

April 24, 2026

2 min read

Tristan Manalac

Stack of coins balancing on seesaw over a bottle of pills.

Drug pricing

Regeneron finally joins Trump’s drug pricing push while notching landmark approval

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, Regeneron is the last to agree—the same day the FDA greenlit its gene therapy for hearing loss in kids.

April 24, 2026

2 min read

Tristan Manalac

rope that is about to break, with eerie background

Opinion

Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust

The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for Biologics Evaluation and Research; it requires accountability, transparency and consistent action.

April 24, 2026

5 min read

Joshua R. Mansbach

Multicolored orbeez balls scattered on a ASMR microphone. Autonomous Sensory Meridian Response. Relaxing sound concept. 3d illustration

Gene therapy

FDA approval of Regeneron’s hearing loss gene therapy breaks barriers

Approved Thursday via the FDA’s Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.

April 23, 2026

4 min read

Heather McKenzie